TWi Biotechnology Merges with DuKang Pharmaceuticals, Capital Increases by NT$960 Million to NT$1.836 Billion

On the 21st, TWi Biotechnology, a company listed on the Emerging Stock Market, held a board meeting and resolved to merge with DuKang Pharmaceuticals through a stock exchange method, with TWi Biotechnology as the surviving entity. The merger still requires approval from the shareholders of both companies, and TWi Biotechnology plans to hold its shareholders’ meeting on June 6, 2025, to vote on the matter. The proposed base date for the merger is set for September 30, 2025, pending regulatory approval.